U
MNTA

UBS’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

UBS’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$7K Sell
600
-100,800
-99% -$1.15M ﹤0.01% 9204
2014
Q2 		$1.23M Buy
101,400
+97,400
+2,435% +$1.15M ﹤0.01% 3360
2014
Q1 		$47K Buy
4,000
+2,500
+167% +$42.3K ﹤0.01% 6933
2013
Q4 		$27K Sell
1,500
-3,200
-68% -$53.8K ﹤0.01% 7782
2013
Q3 		$68K Buy
4,700
+1,600
+52% +$24.5K ﹤0.01% 6462
2013
Q2 		$47K Buy
+3,100
New +$40.9K ﹤0.01% 6817

Other funds holding MNTA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
NTC
North Tide Capital Boston, Massachusetts $469M AUM 6.57% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's MNTA Position: Q3 2014 in Review

UBS increased its Momenta Pharmaceuticals, Inc. (MNTA) stake by 103% in Q3 2014, buying an estimated $879K and bringing the position to 152,100 shares worth $1.73M. The position accounts for ﹤0.01% of the portfolio, ranked #3033.

UBS first reported a position in MNTA in Q2 2013 and has held it in 6 quarters since. The position peaked at $2.81M in Q4 2013. 143 funds tracked by Wall St. Rank hold MNTA as of Q3 2014.

  • UBS held 152,100 shares of Momenta Pharmaceuticals, Inc. worth $1.73M as of Q3 2014.
  • UBS bought 77,043 Momenta Pharmaceuticals, Inc. shares in Q3 2014, an estimated $879K.
  • Momenta Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #3033 holding.
  • UBS first reported a position in Momenta Pharmaceuticals, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Momenta Pharmaceuticals, Inc. position peaked at $2.81M in Q4 2013.
  • 143 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.